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Monday, March 7, 2011 215amechanisms. Since growing crystals of large complexes that are heteroge-
neously glycosylated like the HA/SP-D or HA/SP-A complexes is difficult,
we have undertaken computational studies to model the interactions. Crystal
structures of HA, SP-A, and SP-D with small saccharide ligands offer starting
points for modeling full length complex type or high-mannose glycosylation
using low energy sugar chain conformations derived from solution studies. Fur-
ther computational approaches are used to obtain an ensemble of potential com-
plex structures. Analysis of these structures can give insights into the
mechanisms of inhibition of SP-D and SP-A variants, as well as the specificity
of SP-D and SP-A for certain glycoforms of HA. Measurement of the differ-
ences in glycosylation site occupation and the glycans residing on HA and
SP-A or SP-D is an important adjunct to the molecular modeling. A complete
strategy based on liquid chromatography/tandem mass spectrometry analysis is
underway to investigate the different glycosite and glycoforms present.
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Small Molecule HIV-1 Capsid Inhibitor Design using Hybrid Structure
Based Methods
Sandhya Kortagere, Navid Madani, Marie K. Mankowski, Amy Princiotto,
Kevin Anthony, Luz-Jeannette Sierra, Xiaozhao Wang, David M. Jones, Joel
R. Courter, Eric Stavale, Roger Ptak, Amos B. Smith III,, Julio Martı´n-Garcı´a,
Joseph Sodroski, Simon Cocklin.
Protein-protein interactions (PPI) are fundamental to almost all biological and
pathological processes and therefore represent an important class of therapeutic
targets that can be utilized against multi-drug resistant pathogens such as HIV-
1. The HIV-1 capsid (CA) protein has recently emerged as an attractive target
as it performs essential roles, both regulatory and structural in early and late
stages of the viral life cycle. Hence, small-molecule inhibitors of capsid assem-
bly would be attractive and novel antiretroviral medications. With the latest
crystal structure of the hexameric arrangement of CA monomers, atomic level
details of the CA hexamer interface are now available. The HIV-1 capsid shell
is composed of ~250 CA hexamers and 12 CA pentamers which are arranged in
the form of a fullerene cone. Crystal structure analysis shows a weak associa-
tion between the monomers and hence the interfaces formed between the N-ter-
minal (NTD) and C-terminal domains (CTD) seem attractive as drug targets. In
this study, we targeted the NTD-NTD interface region as a novel PPI to design
inhibitors using the hybrid structure based method. Our preliminary results
show that we have identified two compounds (CK026 and CK422) that display
significant antiretroviral activity against HIV-1. Importantly, these compounds
belong to two distinct inhibitory classes: early-stage inhibitors and late-stage
inhibitors. Compound CK026 represents the first CA-targeted small molecule
that works by disruption of pre-integration events in HIV-1 replication. Further
chemical modification has led to identification of other analogs that retain the
antiviral activity with improved drug like properties.
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Protein Loop Modeling using Distance-Guided Sequential Monte Carlo
Method
Ke Tang, Jinfeng Zhang, Jie Liang.
Modeling loop regions is an important task for protein structure prediction.
We have developed a new loop construction method through efficient sam-
pling with a loop-specific energy function. Based on a new sequential Monte
Carlo sampling strategy called Distance-guided Sequential Monte Carlo
(dSMC), our method efficiently generate loop conformations with lower en-
ergy. To derive the loop-specific energy function, a decoy-based reference
state is used with a large set of loop conformations. Our approach is works
well in modeling long loops. The average smallest global RMSD for 11 res-
idue loops generated is about 1.5 A. Our method also addresses the challeng-
ing problem of multi-loop modeling. As loops often are in spatial proximity
and interact with each other, our approach treats these loops simultaneously
and sample multiple loop efficiently. As an example, for the protein ribonucle-
ase A (PDB id: 7RSA) which has 3 loops (7þ4þ5 residues), the global RMSD
for the loops with the lowest energy compared to the known structure is only
0.52 A.
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Structure Based Inhibition of Mitochondrial Aldehyde Dehydrogenase
(ALDH2) Activity
Ann C. Kimble-Hill, Hina Younus, Samy Meroueh, Thomas D. Hurley.
Mitochondrial aldehyde dehydrogenase (ALDH2) is an enzyme that partici-
pates in multiple metabolic pathways, including the oxidation of toxic biogenic
and environmental aldehydes. Our laboratory is interested in developing novel
and selective ALDH2 inhibitors. We recently identified and studied three dis-
tinct classes of small molecules based on their ability to inhibit ALDH2 activity
(esterase, dehydrogenase, and both). These inhibitors were identified by virtual
screen which consisted of three steps: 1) docking 800,000 ChemBridge mole-cules to the substrate cavity in ALDH2; 2) scoring the receptor-ligand com-
plexes while computing the binding affinity; and 3) ranking the top 1,000
compounds using GlideScore to determine the top 250 compounds for study.
From this list, 112 compounds were selected for purchase and screened for in-
hibitory activity at 50 uM. 19 compounds were selected for further evaluation
based on their ability to inhibit hALDH2 propionaldehyde oxidation by more
than 60%. IC50 values for these compounds were determined using both the
dehydrogenase and esterase assays.
We selected 4 compounds with IC50 values less than 20uM for further kinetic
and structural studies: I32, I72, I76, and I78. These inhibitors show a competi-
tive inhibition pattern toward varied NADþ concentrations and either uncom-
petitive or noncompetitive inhibition towards varied priopionaldehyde
concentrations. Based on their structural similarity and x-ray crystallography
structures obtained with these compounds bound to the enzyme, fragments
were then chosen for studying the mechanism by which they inhibit ALDH2.
The next step is to solve the structures of these fragments bound to ALDH2
and develop SAR data for fragment based compound development that will en-
hance their specificity for and inhibition of ALDH2. This work was supported
by NIH R01-AA18123 and NIH R01-AA18123S1.
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Role of water and G Protein in modulating agonist affinity in GPCRs
Supriyo Bhattacharya, Michiel Niesen, Alfonso R. Lam,
Nagarajan Vaidehi.
Predicting accurate ligand poses and ligand selective receptor conformations
are imperative in designing efficacious, functionally specific drugs for G-pro-
tein coupled receptors. Comparison of the crystal structures of carazolol (in-
verse agonist), formoterol(agonist), and agonist with G-protein mimic bound
b2 Adrenergic Receptor (b2AR) shows that the agonist stabilizes a slightly dif-
ferent conformation when there is no G-protein bound. The G-protein bound
receptor state exhibits a high affinity conformation for the agonist. Using the
computational method LITiCon, we have calculated the activation pathways
for full, partial and inverse agonists of b2AR, which are in agreement with fluo-
rescence intensity lifetime measurements. MD simulations starting from vari-
ous conformations along the activation pathway (total ~1.5 ms) show that in
the absence of G protein, norepinephrine (agonist) stabilizes an intermediate re-
ceptor state that is similar to the formoterol bound intermediate state without
the G-protein, in agreement with the recent crystal structure of formoterol
bound b2AR. Thus coupling to G protein may be needed for stabilizing the
fully active state.
Using Liticon method we have calculated the activation pathway of agonist
bound adenosine receptor A2A starting from its inactive state. We found that
water plays a important role in the docking of the antagonist as well as the ag-
onist.
We recently predicted the structures of D3 dopamine receptor and CXCR4 che-
mokine receptor as part of the competition for the assessment of computational
methods in GPCR modeling (GPCR Dock 2010). The predicted docked poses
of both the ligands are in close agreement with the crystal structures. The de-
tails of the methods and comparison with the crystal structures will be pre-
sented.
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Biophysical Approaches to Discovery of Novel Antibacterial Leads
Gautam Sanyal.
This presentation will outline biophysical approaches to discovery of antibac-
terial lead compounds that are designed to address bacterial resistance to many
current antibiotics. There are a number of essential enzymes, in key pathways
of pathogenic bacteria, which have not been targeted by existing drugs. The po-
tential bacterial selectivity and spectrum of these single gene targets can be val-
idated using structural tools. In addition, inhibiting clinically exploited and
validated bacterial enzymes with a different mechanism (e.g., at a different
binding site) than those offered by current drugs can be a powerful approach.
Target enzymes that have remained unexploited or those that offer alternative
binding sites include cell wall biosynthesis and DNA replication enzymes. In
our discovery efforts, biophysical studies including X-ray crystallography
and NMR spectroscopy are utilized at all stages of lead generation beginning
with target selection, validation, selectivity analysis and probing of target bind-
ing sites for druggability. This will be exemplified with comparative structures
of target enzymes from different pathways. Hits identified through screening of
compound and fragment libraries against these targets are progressed towards
leads with the help of biophysical and structural analysis of protein-ligand com-
plexes. Development of effective screening assays for enzyme targets requires
a thorough understanding of enzyme mechanism. An example will be given of
how water LOGSYmeasurements by NMR explained the mechanism of a mul-
tisubstrate cell wall enzyme. Finally, development of a lead series against
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eration approach will be presented. In this approach, biochemical, biophysical
and structural tools were employed to screen fragment libraries against the tar-
get enzyme and progress initial hits to drug-like leads. The availability of high-
resolution target structure provided valuable chemistry guidance in designing
such leads.
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ROSETTAEPR: An Integrated Tool for Protein Structure Determination
From Sparse EPR Data
Stephanie Hirst, Nathan Alexander, Hassane S. Mchaourab, Jens Meiler.
Membrane proteins remain a particular challenge in structural biology. Only
about 1.5% of reported tertiary structures and 60 unique membrane protein to-
pologies consisting of more than one transmembrane span are represented in
the PDB. However, these proteins make up an estimated 30-40% of the entire
proteome, and over half of all therapeutics target this group. Site-directed spin
labeling electron paramagnetic resonance (SDSL-EPR) is often used for the
structural characterization of proteins that elude other techniques, such as X-
ray crystallography and NMR. However, high-resolution structures are difficult
to obtain due to uncertainty in the spin label location and sparseness of exper-
imental data. ROSETTAEPR has been designed to improve high-resolution
protein structure prediction using sparse SDSL-EPR distance data. The ‘‘mo-
tion-on-a-cone’’ spin label model is converted into a knowledge-based poten-
tial, which was implemented as a scoring term in ROSETTA. We have
demonstrated the feasibility of using ROSETTAEPR with soluble proteins
by benchmarking the method on T4-lysozyme. ROSETTAEPR increased the
fractions of correctly folded models (RMSDC < 7.5A˚) and models accurate
at medium resolution (RMSDC < 3.5A˚) by 25%. After full-atom refinement,
ROSETTAEPR yielded a 1.7A˚ model of T4-lysozyme, thus indicating that
atomic detail models can be achieved by combining sparse EPR data with RO-
SETTA. ROSETTAEPR was also benchmarked on a set of membrane proteins
of known structure. If EPR experimental data were not available, simulated
data were derived from the existing structures. It was generally observed that
de novo folding in the presence of EPR restraints enriched the recovery of
the proteins’ correct topology compared to when folding with no restraints.
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Incorporating the Effects of pH in Protein-Protein Docking
Krishna Praneeth Kilambi, Jeffrey J. Gray.
Highly charged interfaces often frustrate protein-protein docking methods.
Current approaches do not account for changes in the ionization states which
may play a crucial role in binding. Predicting the charges on the residues would
be the first step towards understanding the dependence of docking on pH. We
developed a method to predict the pKa values of the common ionizable residues
in proteins (Asp, Glu, Lys, His and Tyr) . It incorporates conformational flex-
ibility through extensive amino-acid side-chain rotamer sampling and is based
on the Rosetta energy function with an explicit term to account for the proton-
ation state probabilities of the amino-acids. In approximately 80% of the cases,
the method predicts the pKa value of a residue to an accuracy of 1 pH unit from
the experimental value and 95% of the time it predicts a value within 2 units of
pH. The method is comparable in accuracy to the other published computa-
tional pKa prediction methods and is fast enough to be used to dynamically
predict and alter the ionization states of the amino-acid side chains during pro-
tein-protein docking. We expect the new protocol to lead to improvements in
conformational sampling during docking as well as help in the discrimination
and ranking of the generated ensemble of tentative protein complexes.
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Mechanism and Action of Flufirvitide, a Peptide Inhibitor of Influenza
Virus Infection
Hussain Badani, Robert F. Garry, Russell B. Wilson, William C. Wimley.
Influenza is an infectious disease typically transmitted through the air. It is re-
sponsible for seasonal epidemics affecting millions of people, and sporadic
global pandemics. Influenza infection is a membrane fusion-dependant process,
occurring in the endosome of the host cell after viral binding and endocytosis.
The virus-host membrane fusion process is mediated by hemagglutinin (HA),
a viral surface glycoprotein. Studies show that when the virus is subjected to
low pH in the endosome, the HA protein partially unfolds and changes confor-
mation, exposing the fusion initiation region (FIR). A 16 amino acid peptide
sequence (Flufirvitide) derived from the fusion initiation region of the HA pro-
tein has shown effective inhibition of influenza virus infection. It is hypothe-
sized that there is an interaction between the peptide and the FIR which
inhibits fusion of the virus to the host cell. Plaque inhibition assays and animal
studies show high efficacy of the peptide against the virus. We are currently de-
veloping biochemical and biophysical assays to study the interaction between
Flufirvitide and HA. Circular Dichroism studies show that the peptide has a ran-dom coil conformation at pH 7 and higher. To elucidate the mechanism of fu-
sion inhibition, the interaction between peptide and HA is being investigated
with immunodetection, immunoprecipitation, and florescence techniques. Ad-
ditionally, binding and interaction of the peptide with the intact virus is being
studied by using Cryo-electron microscopy.
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Computational Design of Small Molecules with Druglike Properties
D.S. Dalafave, K.S. Jani.
Many cancers overexpress antiapoptotic proteins,which can lead to poor chemo-
therapy response. This work reports on computational design of druglike small
molecules that could potentially facilitate apoptosis by forming complexes with
antiapoptotic proteins. Drugs based on small molecules that target a single pro-
tein can lead to drug resistance. On the other hand, a drug that operates too
broadly may harm healthy tissue. An alternative is a drug that can bind two or
more of the proteins. A single drug would be more economical and lead to fewer
side effects than a combination of drugs with each one targeting a single protein.
In this work, structures of experimentally known small molecules were used as
templates to design new molecules. Common structural features of the experi-
mental molecules were identified. The Osiris Property Explorer program was
employed to study how the features influenced molecular druglike properties.
Atomic substitutions and structuralmodificationswere done to design new small
molecules.Drug-related properties andpotential toxicities of themoleculeswere
determined and compared to those of commercial drugs. Molecules with no in-
dicated toxic risks and optimal values of drug-related properties were used for
docking studies in the ArgusLab program. Binding energies of stable configura-
tions of the designed molecules and antiapoptotic proteins were calculated. De-
signed molecules that made the most stable complexes with two or more
antiapoptotic proteins were identified. The potential to use the designed mole-
cules in anticancer drug design is discussed.
1182-Pos Board B92
Total Synthesis of Moscatilines and Wedelolactones as Potential Inhibitors
of Anti-Metastic Agents in MDA-MB-231 Cells
Yean-Jang Lee, Wen-Shing Tsau, Chia-Fu Cheng, Tsui-Hwa Tseng,
Pei-Yun Huang, Shien-Kai Chuang.
Combretastatins, which are an important group of anticancer drugs, were iso-
lated by Pettit et al. from the African tree Combretum caffrum in 1989. Addi-
tionally, Liang et al. have reported that ten coumestans were isolated from the
roots of Hedysarum multijugum, which is a plant in Hedysarum Linn. of the
family Leguminosae used as a folk herbal drug in northwest China. Coumestans
comprise a class of naturally occurring products with a variety of biological ac-
tivities including phytoestrogenic, antibacterial, antifungal, antimyotoxic, and
phytoalexine effects. Due to their biological activities, the synthesis of Hedy-
sarimcoumestan B is achieved in which the longest linear sequence is only
eight steps in 50% overall yield from commercially available phloroglucinol.
The key transformations in the synthesis are Stille coupling and DDQ oxida-
tive-cyclization reactions. This synthetic strategy can be applied to give access
to the demethylwedelolactone and wedelolactone, which were afforded from a-
bromocoumarin in high 55% and 47% yields, respectively. In addition, CA-4
analogues are also synthesized by Pd-catalyzed coupling in overall yield
20~28%. Furthmore, the molecular model was examined the interactions of
proteins and ligands as well. Finally, the bioassay results show that the anti-in-
vasion and anti-metastsis activity of wedelolactones in breast cancer are asso-
ciated with inhibition of signaling pathway and promotion of chromatin
remodeling. Camphorataimide B reduced the size and weigth of lung as well
as lung colonization of MDA-MB-231 cells.
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In Silico Approach to Identify Substrates and Inhibitors of Malaria Prote-
ases
Lauren E. Boucher, Jenny Lundqvist, Holly L. Hammond, Ju¨rgen Bosch.
Malaria affects over 500 million people and causes 1.3 million deaths annually.
The parasite, Plasmodium falciparum, is responsible for the most deadly vari-
ant of malaria in humans. Due to evolving resistance to current treatments, it is
necessary to develop new drugs targeting the parasite. Potential drug targets are
the malaria proteases; several proteases are critical in both the liver and blood
stages of the parasite’s life cycle, essential for both invasion and egress of cells.
Proteases have been effective drug targets for the treatment of several diseases
evidenced by the development of HIV protease inhibitors, ACE inhibitors treat-
ing hypertension, and anticoagulants treating thrombosis.
In developing new therapies, we are taking a structure-based drug design ap-
proach to design inhibitors of proteases key to parasite survival. While several
vital proteases have been identified, relatively little else is known and substrates
for many proteases have yet to be identified. To identify these substrates, we are
using an in silico approach to screen for peptides that bind to the protease active
